{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:25:58Z","timestamp":1785205558651,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40120-023-00452-1","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T15:03:13Z","timestamp":1677596593000},"page":"669-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"12","author":[{"given":"Payam","family":"Tabaee Damavandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Giossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Matricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Meletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","volume":"346","author":"OC Cockerell","year":"1995","unstructured":"Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346:140\u20134.","journal-title":"Lancet"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Russo E, Del Giovane C, Silvestrini M, Brigo F. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82:199\u2013218.","journal-title":"Drugs"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/epi.13723","volume":"58","author":"CB Josephson","year":"2017","unstructured":"Josephson CB, Patten SB, Bulloch A, Williams JVA, Lavorato D, Fiest KM, Secco M, Jette N. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58:764\u201371.","journal-title":"Epilepsia"},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2165\/00003495-197510040-00001","volume":"10","author":"RM Pinder","year":"1975","unstructured":"Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs. 1975;10:241\u2013323.","journal-title":"Drugs"},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","volume":"95","author":"RB Rothman","year":"2002","unstructured":"Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 2002;95:73\u201388.","journal-title":"Pharmacol Ther"},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM199608293350901","volume":"335","author":"L Abenhaim","year":"1996","unstructured":"Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609\u201316.","journal-title":"N Engl J Med"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581\u20138.","journal-title":"N Engl J Med"},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM198511283132219","volume":"313","author":"J Aicardi","year":"1985","unstructured":"Aicardi J, Gastaut H. Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med. 1985;313:1419.","journal-title":"N Engl J Med"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1756285615607726","volume":"8","author":"A-N Schoonjans","year":"2015","unstructured":"Schoonjans A-N, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015;8:328\u201338.","journal-title":"Ther Adv Neurol Disord"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","volume":"53","author":"B Ceulemans","year":"2012","unstructured":"Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131\u20139.","journal-title":"Epilepsia"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/epi.13407","volume":"57","author":"B Ceulemans","year":"2016","unstructured":"Ceulemans B, Schoonjans A-S, Marchau F, Paelinck B, Lagae L. Five-year extended follow-up of 10 Dravet patients treated with fenfluramine. Epilepsia. 2016;57:e129\u201334.","journal-title":"Epilepsia"},{"key":"452_CR12","doi-asserted-by":"crossref","unstructured":"Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24(2):309\u2013314.","DOI":"10.1111\/ene.13195"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","volume":"33","author":"AS Schoonjans","year":"2017","unstructured":"Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33:1773\u201381.","journal-title":"Curr Med Res Opin"},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.","journal-title":"Syst Rev"},{"key":"452_CR15","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). London: The Cochrane Collaboration; 2011. http:\/\/handbook-5-1.cochrane.org\/. Accessed Dec 2021."},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320.","journal-title":"CNS Drugs"},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40263-018-0504-x","volume":"32","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Grillo E, Cagnetti C, Verrotti A, Zaccara G, et al. Adjunctive eslicarbazepine acetate in pediatric patients with focal epilepsy: a systematic review and meta-analysis. CNS Drugs. 2018;32:189\u201396.","journal-title":"CNS Drugs"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","volume":"265","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733\u201340.","journal-title":"J Neurol"},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00415-017-8505-0","volume":"264","author":"S Lattanzi","year":"2017","unstructured":"Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017;264:1697\u2013704.","journal-title":"J Neurol"},{"key":"452_CR22","doi-asserted-by":"crossref","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 2018;45:193\u2013203.","DOI":"10.1159\/000488401"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B, FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243\u201354.","journal-title":"Lancet"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S, FAiRE, DS Study Group. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77:300\u20138.","journal-title":"JAMA Neurol"},{"key":"452_CR25","doi-asserted-by":"crossref","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox\u2013Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79:554\u201364.","DOI":"10.1001\/jamaneurol.2022.0829"},{"key":"452_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989","volume":"105","author":"P Martin","year":"2020","unstructured":"Martin P, de Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105: 106989.","journal-title":"Epilepsy Behav"},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fphar.2017.00191","volume":"8","author":"J Sourbron","year":"2017","unstructured":"Sourbron J, Smolders I, de Witte P, Lagae L. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.","journal-title":"Front Pharmacol"},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.3390\/ijms22168416","volume":"22","author":"P Martin","year":"2021","unstructured":"Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22:8416.","journal-title":"Int J Mol Sci"},{"issue":"pt A","key":"452_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108024","volume":"121","author":"KI Bishop","year":"2021","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome. Epilepsy Behav. 2021;121(pt A): 108024.","journal-title":"Epilepsy Behav"},{"key":"452_CR30","doi-asserted-by":"crossref","unstructured":"Bishop KI, Isquith PK, Gioia GA, et al. FINTEPLA (fenfluramine) treatment improves everyday executive functioning in patients with Lennox\u2013Gastaut syndrome: analysis from a phase 3 clinical trial. Presented at American Academy of Neurology Annual Meeting; 2021 Apr 17\u201322; virtual meeting.","DOI":"10.1055\/s-0041-1739606"},{"issue":"138","key":"452_CR31","volume":"1","author":"KI Bishop","year":"2022","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Nabbout R, Specchio N, Sullivan J, Auvin S, Helen Cross J, Guerrini R, Farfel G, Galer BS, Gammaitoni AR. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome. Epilepsy Behav. 2022;1(138): 108994.","journal-title":"Epilepsy Behav"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","volume":"77","author":"YT Ng","year":"2011","unstructured":"Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA, OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77:1473\u201381.","journal-title":"Neurology"},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","volume":"70","author":"T Glauser","year":"2008","unstructured":"Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950\u20138.","journal-title":"Neurology"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/08830738060210062101","volume":"21","author":"C Chiron","year":"2006","unstructured":"Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496\u2013502.","journal-title":"J Child Neurol"},{"key":"452_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34:229\u201341.","journal-title":"CNS Drugs"},{"key":"452_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","volume":"32","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32:905\u201316.","journal-title":"CNS Drugs"},{"key":"452_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/epi.16546","volume":"61","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, Zaccara G, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia. 2020;61:1090\u20138.","journal-title":"Epilepsia"},{"key":"452_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108212","volume":"122","author":"A Gil-Nagel","year":"2021","unstructured":"Gil-Nagel A, Sullivan J, Ceulemans B, et al. Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy Behav. 2021;122: 108212.","journal-title":"Epilepsy Behav"},{"key":"452_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.seizure.2020.12.016","volume":"85","author":"IK Sharawat","year":"2021","unstructured":"Sharawat IK, Panda PK, Kasinathan A, Panda P, Dawman L, Joshi K. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: a systematic review and meta-analysis. Seizure. 2021;85:119\u201326.","journal-title":"Seizure"},{"key":"452_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ane.13387","volume":"143","author":"L Zhang","year":"2021","unstructured":"Zhang L, Li W, Wang C. Efficacy and safety of fenfluramine in patients with Dravet syndrome: a meta-analysis. Acta Neurol Scand. 2021;143:339\u201348.","journal-title":"Acta Neurol Scand"},{"key":"452_CR41","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/epi.16722","volume":"61","author":"J Sullivan","year":"2020","unstructured":"Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla.) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020;61:2396\u2013404.","journal-title":"Epilepsia"},{"key":"452_CR42","doi-asserted-by":"crossref","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2023;64:139\u2013151.","DOI":"10.1111\/epi.17431"},{"key":"452_CR43","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/epi.16638","volume":"61","author":"WW Lai","year":"2020","unstructured":"Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61:2386\u201395.","journal-title":"Epilepsia"},{"key":"452_CR44","doi-asserted-by":"crossref","unstructured":"Agarwal A, Farfel GM, Gammaitoni AR, Wong PC, Pinto FJ, Galer BS. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments. Eur J Paediatr Neurol. 2022;39:35\u20139.","DOI":"10.1016\/j.ejpn.2022.05.006"},{"key":"452_CR45","first-page":"e98","volume":"7","author":"O Devinsky","year":"2021","unstructured":"Devinsky O, King L, Schwartz D, Conway E, Price D. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021;7:e98\u2013102.","journal-title":"Epilepsia"},{"key":"452_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2021.100461","volume":"16","author":"D Millett","year":"2021","unstructured":"Millett D, Pach S. Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome. Epilepsy Behav Rep. 2021;16: 100461.","journal-title":"Epilepsy Behav Rep"},{"key":"452_CR47","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/acn3.50921","volume":"6","author":"A Aeby","year":"2019","unstructured":"Aeby A, Sculier C, Bouza AA, Askar B, Lederer D, Schoonjans AS, Vander Ghinst M, Ceulemans B, Offord J, Lopez-Santiago LF, Isom LL. SCN1B-linked early infantile developmental and epileptic encephalopathy. Ann Clin Transl Neurol. 2019;6:2354\u201367.","journal-title":"Ann Clin Transl Neurol"},{"key":"452_CR48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/dmcn.14965","volume":"63","author":"KR Geenen","year":"2021","unstructured":"Geenen KR, Doshi SP, Patel S, Sourbron J, Falk A, Morgan A, Vu U, Bruno PL, Thiele EA. Fenfluramine for seizures associated with Sunflower syndrome. Dev Med Child Neurol. 2021;63:1427\u201332.","journal-title":"Dev Med Child Neurol"},{"key":"452_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106777","volume":"177","author":"S Tupal","year":"2021","unstructured":"Tupal S, Faingold CL. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP. Epilepsy Res. 2021;177: 106777.","journal-title":"Epilepsy Res"},{"key":"452_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","volume":"93","author":"JH Cross","year":"2021","unstructured":"Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, Schoonjans AS, Donner E, Wirrell E, Kothare S, Agarwal A, Lock M, Gammaitoni AR. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154\u20139.","journal-title":"Seizure"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00452-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00452-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:40:21Z","timestamp":1679920821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00452-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00452-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"7 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}